ReviewClinical & experimental metastasis2021
Breast cancer liver metastasis: current and future treatment approaches.
Review in Clinical & experimental metastasis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06093022 (Surgical or Medical Treatment of Breast Cancer Metastasis), which is not on this map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Objective Response and Disease Control Rates in Patients with Liver Metastastic Breast Cancer Receiving Transarterial Radioembolization: A Meta-Analysis.Current oncology (Toronto, Ont.) · 2024Pooled it
- Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial.Nature communications · 2026Trial
- Therapeutic potential of colchicine-binding site inhibitors in breast cancer brain metastasis.Cancer letters · 2026Review
- Exosome-mediated organotropism in breast cancer metastasis: bridging the gap between molecular mechanisms and clinical application.Clinical & experimental metastasis · 2026Review
- HER2-low metastatic breast cancers: clinic-pathological characteristics, metastatic sites, and survival impact on biomarker discordance.Virchows Archiv : an international journal of pathology · 2026Article
- Circulating Extracellular Vesicles Reflect Dynamic Shifts in Liver Transcriptome Following Tumour Resection.Cancers · 2026Article
- Ammonia Detoxification Inhibits Liver Metastasis by Reshaping Hepatic Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Impact of Underlying Liver Disease on the Risk and Prognostic Factors of Breast Cancer Liver Metastases: A Retrospective Multicenter Cohort Study.Cancer medicine · 2026Article
- Integrative multi-omics analysis identifies PAICS as a key regulator of epithelial-mesenchymal transition in breast cancer metastasis.Discover oncology · 2026Article
- Individualized prediction of survival after brain metastasis development in patients with breast cancer.Journal of neuro-oncology · 2026Article
- Nobiletin and polydatin synergistically alleviate triple-negative breast cancer liver metastasis via suppressing ECM1a-mediated fatty acid biosynthesis.Acta pharmacologica Sinica · 2026Article
- Yttrium-90 for the treatment of breast cancer liver metastases: a global propensity-matched study.Proceedings (Baylor University. Medical Center) · 2026Article
- Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study.Frontiers in oncology · 2026Article
- Development and validation of a machine learning model to evaluate survival in patients with newly diagnosed breast cancer with liver metastasis.Frontiers in oncology · 2026Article
- Case Report: Liver Metastasis from Ductal Carcinoma In Situ of the Breast.International medical case reports journal · 2026Article
- Photothermal Combination Therapy for Metastatic Breast Cancer: A New Strategy and Future Perspectives.Biomedicines · 2025Review
- Review
- Metastatic Breast Cancer mHealth App to Promote Patient-Provider Communication: Protocol for a Usability and Satisfaction Study.JMIR research protocols · 2025Article
- Long-term survival outcomes and subtype variations between primary breast cancer and liver metastases in 542 patients with advanced breast cancer: insights from a real-world analysis.Discover oncology · 2025Article
- Bridging molecular insights and clinical application: non-coding RNAs, targeted drug delivery, and metastatic breast cancer therapy.Discover oncology · 2025Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Nearly all fatalities arising from breast tumors are attributable to distant metastases. Breast cancer liver metastasis (BCLM) is associated with poor prognoses, with the median survival time being 2 to 3 years. Tumor intrinsic subtype directs preferential metastasis to specific organs, with HER2-enriched tumors demonstrating the highest rates of metastasis to the liver, though all subtypes can grow in the liver. There is no singular established standard-of-care for BCLM; therapeutic selection is driven by histologic and molecular hallmarks of the primary tumor or biopsied metastasis samples. Given the poor prognosis of patients with hepatic spread, pre-clinical studies are necessary to identify and evaluate promising new treatment strategies. It is critical that these laboratory studies accurately recapitulate the BCLM disease process, standard progression, and histological attributes. In this review, we summarize the histologic and molecular characteristics of BCLM, evaluate the efficacy of existing surgical and medical treatment strategies, and discuss future approaches to preclinical study of BCLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.